Table 8.
Antimicrobial susceptibility (percentage) of Gram-positive bacteria causing bloodstream infection
| Drug | S. aureus | E. faecium* | E. faecalis* | |||
| CA 13 | HA 17 | CA 12 | HA 9 | CA 9 | HA 6 | |
| Penicillin | 0 | 0 | 10 | 0 | 17 | 75 |
| Ampicillin* | - | - | 25 | 11 | 100 | 100 |
| Amoxicillin-clavulanate | 77 | 50 | 70 | 11† | 100 | 100 |
| Cloxacillin | 92 | 88 | - | - | - | - |
| Cefuroxime | 92 | 88 | - | - | - | - |
| Ceftazidime | 85 | 80 | - | - | - | - |
| Meropenem | 100 | 100 | - | - | - | - |
| Gentamicin* | 100 | 81 | 67 | 33 | 56 | 67 |
| Vancomycin* | 100 | 100 | 100 | 100 | 100 | 100 |
| Erythromycin | 100 | 71 | 0 | 0 | 22 | 33 |
| Doxycycline | 62 | 35 | 9 | 0 | 25 | 0 |
| Co-trimoxazole | 69 | 63 | 27 | 0 | 67 | 40 |
| Chloramphenicol | 85 | 73 | 50 | 11 | 38 | 33 |
| Ciprofloxacin* | 77 | 81 | 42 | 22 | 100 | 100 |
| Linezolid* | - | - | 100 | 100 | 100 | 100 |
| Quinupristin-dalfopristin* | - | - | 100 | 100 | 0 | 17 |
CA, community-acquired infection; HA, hospital-acquired infection; "-", not done. *E-test was used for susceptibility testing of enterococci against ampicillin, ciprofloxacillin, linezolid, quinupristin-dalfopristin, vancomycin and high-level gentamicin resistance. † Statistically significant difference in susceptibility among hospital-acquired and community-acquired isolates, p < 0.05 by two-sided Fisher's exact test.